CSG's Multi-Front Defence Expansion Fails to Halt 17% Weekly Rout as Technicals Flash Warning

Despite new NATO fuze contracts, Ukraine shell line, and Alzchem stake, CSG shares fell 17% to near 52-week low, down 58% from peak.

For a company that just activated a new shell line in Ukraine, secured two fresh NATO fuze contracts, and expanded its strategic stake in a specialty chemicals maker, the share price performance tells a jarringly different story. Shares in Czechoslovak Group have shed nearly 17% in seven trading sessions, closing at €15.05 on Friday — a stone's throw from their 52-week low of €13.65 touched on 4 May. The stock now stands 58.26% below the January peak of €36.05, and trades 23.44% under its 50-day moving average of €19.66.

The slide has pushed the relative strength index to 31.8, deep into oversold territory, while the 30-day annualised volatility has ballooned to 76.98% — underscoring just how febrile sentiment around the defence contractor has become. The market's mood stands in stark contrast to the operational momentum CSG is generating across multiple theatres.

Last week alone, the group announced two long-term contracts from European NATO members for mechanical and electronic fuses for large-calibre ammunition, carrying a combined value in the high tens of millions. Deliveries are scheduled to start before year-end. The electronic fuses will be produced at a new facility in Slovakia, a joint venture with South Africa's Reunert called Fuchs Electronics Europe, in which Reunert holds 51% and CSG contributes its ZVS Dubnica nad Váhom site as an in-kind stake. Crucially, the factory is designed to supply not just CSG but also other European ammunition makers, widening its addressable market.

That fuze venture runs in parallel with other Slovak projects: a new line for long-range ammunition now running at full capacity of 70,000 units per year, and the broader ramp-up of large-calibre shell production. CSG aims to lift its own output to 850,000 rounds by year-end, up from 550,000 in 2025, with a further 400,000 rounds sourced from reactivated capacity.

Across the border in Ukraine, a new production line began operations on 1 June under a licensing partnership with Ukrainian Armor. It will produce NATO-standard 155mm artillery shells at an annual rate of 100,000 units, alongside 50,000 105mm rounds, with technology and high-value components supplied from Czechia and final assembly performed locally.

Meanwhile, CSG has continued to build its position in the German specialty chemicals group Alzchem, a producer of nitroguanidine — a critical raw material for propellants and munitions. The group now holds 20.1% of Alzchem's voting rights, comprising a direct stake of 9.9% through subsidiary STALUNA TRADE and total return swaps on a further 10.2% that run until May 2027 but carry no voting rights. CSG has pitched itself as a long-term investor in Alzchem.

The most ambitious move remains unconfirmed: according to Reuters, CSG has signalled interest in taking a stake in the Franco-German KNDS, a leading European manufacturer of tanks and artillery systems. However, KNDS's German family shareholders are understood to favour an initial public offering and are open to a participation by the German federal government. Neither the size nor the valuation of any potential transaction has been disclosed.

All of this sits atop a fundamental base that, on paper, looks robust. First-quarter revenue rose 13.8% year-on-year to €1.544bn, net profit surged 83% to €299m, and the net margin improved from 12% to 19%. The order backlog hit a record €17bn, with a further €27bn in early-stage negotiations. Management reaffirmed its full-year guidance for sales of €7.4-7.6bn and an adjusted EBIT margin of 24-25%.

Despite that, Berenberg recently trimmed its estimates and lowered its price target, citing uneven segment performance in the first quarter. Ten analysts still have a "Strong Buy" rating on the stock, with a median target of €32.05 — more than double the current price. But the market appears to be demanding more than promises. Whether the Alzchem position evolves into a visible industrial partnership, whether the KNDS approach gains traction, and whether the operating momentum can overcome the current technical malaise — these questions will shape the narrative until the half-year results on 7 August. The quiet period begins 8 July. Until then, the chasm between operational reality and market perception remains the defining feature of CSG's stock.